<DOC>
	<DOCNO>NCT02654899</DOCNO>
	<brief_summary>The current study first clinical trial propose PF-06815345 . It design evaluate safety , tolerability , pharmacokinetics ( PK ) follow administration single oral dos PF-06815345 healthy adult subject .</brief_summary>
	<brief_title>Single Dose Study PF-06815345 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Healthy male female nonchildbearing potential ; Age 1855 , inclusive ; Body Mass Index 17.534.9 kg/m2 , inclusive ; Body weight &gt; 50 kg ; Not prescription nonprescription drug within 7 day 5 halflives prior first dose . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergises , exclude untreated , asymptomatic , seasonal allergy time dose )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Healthy subject</keyword>
	<keyword>Single Ascending Dose</keyword>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Dyslipidemia</keyword>
</DOC>